Senzime AB (publ.) is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
06/07/26	SEK 4.325	+0.58%	88,951
03/07/26	SEK 4.300	+1.42%	89,093
02/07/26	SEK 4.240	+0.95%	127,021
01/07/26	SEK 4.200	-3.00%	173,210
30/06/26	SEK 4.330	+1.29%	58,221

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm Other stock markets 17:00:00 06/07/2026 BST			5-day change	1st Jan Change
4.325 ^SEK	+0.58%		+1.17%	-19.91%

06-05	Senzime Launches Tetraanalytics Data Analytics Platform and Showcases Expanded Tetragraph Capabilities At Euroanaesthesia 2026	CI
06-03	Senzime secures new agreement with U.S. children's hospital	FW

Market Cap	676M 70.09M 61.27M 56.31M 52.49M 99.56M 6.67B 101M 263M 3.28B 263M 257M 11.3B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	676M 70.09M 61.27M 56.31M 52.49M 99.56M 6.67B 101M 263M 3.28B 263M 257M 11.3B	EV / Sales 2026 *	4.43x	EV / Sales 2027 *	2.91x
Free-Float	40.74%	Yield 2026 *	-	Yield 2027 *	-

06-05	Senzime Launches Tetraanalytics Data Analytics Platform and Showcases Expanded Tetragraph Capabilities At Euroanaesthesia 2026	CI
06-03	Senzime secures new agreement with U.S. children's hospital	FW
06-01	Senzime launches more sustainable EMG sensor	FW
05-27	Senzime gets additional FDA class II 510(k) clearance for Tetragraph system	RE
05-27	Senzime Secures Additional US FDA Clearance for TetraGraph Monitoring System	MT
05-27	Senzime receives FDA clearance for expanded Tetragraph system	FW
05-27	Senzime receives FDA 510(k) clearance for expanded Tetragraph system functionality	FW
05-27	Senzime Obtains FDA 510(k) Clearance For Enhanced TetraGraph System	CI
05-19	Senzime AB Elects Wolfgang Reim as Members of the Board of Directors	CI
04-29	Senzime bolsters US expansion with new Head of Sales	FW
04-24	Senzime's TetraGraph System Joins Catalogs of Three US Group Purchasing Organizations	MT
04-24	Senzime's TetraGraph system contracted on three GPO agreements in U.S.	RE
04-24	Senzime's TetraGraph system included in three U.S. procurement agreements	FW

04/09/25	Redeye Initiates Coverage of Senzime with a Target Value of SEK 12	FW
03/06/25	DNB Carnegie believes that Senzime's targeted issue is sufficient to achieve positive free cash flow.	FW
13/05/24	Senzime's order intake supports long-term growth case - Penser	FW
19/02/24	Strong growth expected from Senzime also in 2024 - Penser	FW
27/10/23	Penser reiterates motivated value for Senzime	FW

Senzime AB Share Price

Stocks

SEZI

SE0002478776

Medical Equipment, Supplies & Distribution

Valuation: Senzime AB

Chart: Senzime AB

Latest news : Senzime AB

Last Transcript: Senzime AB

Analysts' recommendations: Senzime AB

Press Releases: Senzime AB

Quotes and Performance

Course Extremes

Managers and Directors: Senzime AB

Latest insider transactions

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

06-29	Senzime : TetraGraph system receives ANVISA regulatory approval in Brazil	PU
06-29	Senzime’s TetraGraph system receives ANVISA regulatory approval in Brazil	AQ
06-05	Senzime to Showcase Expanded TetraGraph Capabilities with Launch of TetraAnalytics at Euroanaesthesia 2026	AQ
06-03	Senzime strengthens position in pediatric anesthesia by securing another hospital contract and highlighting positive outcome data	AQ
06-01	Senzime Advances Sustainable Anesthesia Monitoring with Launch of New EMG Sensor	AQ

1 day	+0.58%
1 week	+1.17%
Current month	-0.12%
1 month	+1.05%
3 months	+3.22%
6 months	-17.93%
Current year	-19.91%

1 week	4.16	4.35
1 month	4.12	4.68
Current year	3.85	6
1 year	3.85	7.38
3 years	3.6	9.6
5 years	2.6	25.8
10 years	2.6	28.5

Manager	Title	Age	Since
Philip Axel Wilhelm Siberg CEO	Chief Executive Officer	53	02/05/2023
Slavoljub Grujicic DFI	Director of Finance/CFO	56	31/12/2021
Fredrik Norrby CTO	Chief Tech/Sci/R&D Officer	50	31/12/2022

Director	Title	Age	Since
Lars Adam Holger Dahlberg CHM	Chairman	53	02/05/2023
Sorin Brull BRD	Director/Board Member	70	31/12/2015
Eva Walde BRD	Director/Board Member	63	04/03/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
12-08	Lars Axelson	Buy	Director	15,000	0.0095%
12-08	Lars Axelson	Sell	Director	15,000	0.0095%
11-27	Lars Axelson	Sell	Director	15,900	0.0101%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SENZIME AB	+0.58%	+1.17%	-19.76%	+4.98%	70.09M
ABBOTT LABORATORIES	-0.73%	+2.07%	-29.22%	-11.73%	166B
MEDTRONIC PLC	-0.75%	+1.83%	-6.00%	-4.25%	106B
CENCORA, INC.	-0.13%	+4.84%	-2.39%	+53.64%	57.69B
HOYA CORPORATION	-1.37%	0.00%	+53.74%	+52.32%	53.78B
BECTON, DICKINSON AND COMPANY	-1.52%	+0.14%	-10.14%	-39.97%	43.56B
MEDLINE INC.	-1.17%	+7.88%	-	-	36.52B
DEXCOM, INC.	+0.58%	+1.44%	-14.41%	-44.41%	27.49B
WEST PHARMACEUTICAL SERVICES, INC.	-1.61%	+1.70%	+62.86%	-3.36%	25.84B
STERIS PLC	-2.15%	-0.04%	-8.64%	-2.43%	21.27B
Average	-0.83%	+4.44%	+2.89%	+0.53%	53.89B
Weighted average by Cap.	-0.87%	+3.80%	-4.26%	+0.81%

	2026 *	2027 *
Net sales	153M 15.83M 13.84M 12.72M 11.86M 22.49M 1.51B 22.83M 59.36M 741M 59.43M 58.15M 2.55B	232M 24.09M 21.06M 19.35M 18.04M 34.21M 2.29B 34.73M 90.31M 1.13B 90.41M 88.47M 3.88B
Net income	-65.3M -6.77M -5.92M -5.44M -5.07M -9.62M -645M -9.76M -25.39M -317M -25.41M -24.87M -1.09B	-26.3M -2.73M -2.38M -2.19M -2.04M -3.87M -260M -3.93M -10.22M -128M -10.24M -10.02M -440M
Net Debt	-	-